HEDRICK ERIC,MODY TARAK D,BUGGY JOSEPH J,LOURY DAVID J,ELIAS LAURENCE,FYFE GWEN
申请号：
NZ60404011
公开号：
NZ604040A
申请日:
2011.06.03
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) (an inhibitor of Bruton&rsquo；s tyrosine kinase (Btk)) for the manufacture of a medicament for the treatment of mantle cell lymphoma in an individual who has already received at least one prior therapy for mantle cell lymphoma, wherein the medicament is suitable for oral administration once per day of a dose of about 420 mg to about 840 mg. Also disclosed it the use of ibrutinib for the manufacture of a medicament for the treatment of relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic leukemia in an individual, wherein the medicament is suitable for oral administration once per day of a dose of about 420 mg to about 840 mg, and wherein the medicament optionally further comprises an additional cancer treatment regimen comprising bendamustine, bortezomib, CAL-101, chlorambucil, cyclophosphamide, dexamethasone, docetaxel, doxorubicin, endostatin, everolimus, etoposide, fludarabine, fostamatinib, hydroxydaunorubicin, ibritumomab, ifosphamide, lenalidomide, mesalazine, ofatumumab, paclitaxel, pentostatin, prednisone, rituximab, temsirolimus, thalidomide, tositumomab, vincristine, or a combination thereof, such as rituximab, fludarabine and cyclophosphamide, or rituximab, cyclophosphamide, hydroxdaunorubicin, vincristine and prednisone.
